Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

KROS has been the topic of several other research reports. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday. Bank of America boosted their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Finally, TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock opened at $11.30 on Friday. The stock has a market capitalization of $344.27 million, a P/E ratio of 6.21 and a beta of 0.87. The business has a 50 day simple moving average of $17.41 and a two-hundred day simple moving average of $17.07. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37). Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. During the same period in the prior year, the firm earned ($1.14) earnings per share. The business’s revenue was down 87.2% on a year-over-year basis. As a group, research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Keros Therapeutics by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after acquiring an additional 87,129 shares during the period. Western Standard LLC grew its holdings in shares of Keros Therapeutics by 42.7% in the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after purchasing an additional 654,989 shares during the period. Geode Capital Management LLC grew its holdings in shares of Keros Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 829,297 shares of the company’s stock valued at $11,073,000 after purchasing an additional 23,112 shares during the period. Jacobs Levy Equity Management Inc. increased its position in Keros Therapeutics by 26.6% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock worth $15,645,000 after purchasing an additional 161,336 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics News Summary

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated a Buy on Keros, providing third‑party validation that could support upside if clinical/commercial progress continues. Keros Therapeutics (KROS) Receives a Buy from Leerink Partners
• Positive Sentiment: Keros posted an updated investor presentation that highlights the rinfatercept strategy and commercialization plan — helpful for investors wanting clarity on timing, positioning and milestones for the lead program. Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
• Neutral Sentiment: Coverage pieces projecting long‑range outcomes (FY2030 estimates) were published; these sets of forecasts are informative but distant and less likely to move the stock by themselves unless they change near‑term guidance. Analysts Offer Predictions for KROS FY2030 Earnings
• Negative Sentiment: HC Wainwright cut multiple near‑term quarterly and multi‑year EPS forecasts (notable downward revisions for 2026–2029 and mixed adjustments to FY2026), signaling weaker anticipated profitability and increasing uncertainty around financial trajectory. HC Wainwright Cuts Estimates
• Negative Sentiment: Wall Street Zen lowered KROS to a Sell, adding downside pressure from the sell‑side and potentially prompting some holders to reduce exposure. Keros Therapeutics (NASDAQ:KROS) Lowered to Sell Rating by Wall Street Zen
• Negative Sentiment: Recent quarterly results showed a significant revenue miss and an EPS shortfall (reported March 4), which remain a material near‑term negative underpinning analysts’ downward estimate revisions and investor caution. KROS Recent Earnings Report

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.